CHRO (Chromocell Therapeutics) Days Payable : 0.00 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Days Payable?

Chromocell Therapeutics's average Accounts Payable for the three months ended in Jun. 2024 was $1.62 Mil. Chromocell Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2024 was $0.00 Mil.

The historical rank and industry rank for Chromocell Therapeutics's Days Payable or its related term are showing as below:

CHRO's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 134.39
* Ranked among companies with meaningful Days Payable only.

Chromocell Therapeutics's Days Payable stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00). stayed the same

Chromocell Therapeutics Days Payable Historical Data

The historical data trend for Chromocell Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Days Payable Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Days Payable

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Days Payable	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Chromocell Therapeutics's Days Payable

For the Biotechnology subindustry, Chromocell Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chromocell Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chromocell Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Chromocell Therapeutics's Days Payable falls into.

Chromocell Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Chromocell Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.994	+	4.621)	/	2 )	/	0	*	365
=	3.8075					/	0	*	365
=	N/A

Chromocell Therapeutics's Days Payable for the quarter that ended in Jun. 2024 is calculated as:

	Days Payable (Q: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2024 )	+	Accounts Payable (Q: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
=	( (2.408	+	0.835)	/	2 )	/	0	*	365 / 4
=	1.6215					/	0	*	365 / 4
=	N/A

Chromocell Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics Headlines

From GuruFocus

Chromocell Announces Stock Repurchase Plan

By Marketwired • 08-07-2024